Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Qiagen N.V.. (9/11/23). "Press Release: Qiagen Launches API to Streamline Access to World-leading Biomedical Data for AI Integration". Venlo & Redwood City, CA.

Organisations Organisation Qiagen Digital Insights (business unit)
  Group Qiagen (Group)
  Organisation 2 Qiagen N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)
  Group Qiagen (Group)
Products Product Qiagen Knowledge Base
  Product 2 Ingenuity Pathways Analysis (IPA) s/w
Persons Person Sheldon, Jonathan (Qiagen 202001 SVP Qiagen Digital Insights before InforSense 200408)
  Person 2 Gilardi, John (Qiagen 201211 Investor Relations)

> API gives easier access to QIAGEN Biomedical Knowledge Base, used by over 40,000 researchers

> Structured content from over 20 years of curation has been cited in over 57,000 scientific papers

> Enables large and small pharma and biotech companies to access vital data for drug discovery and other insights

QIAGEN Digital Insights, the bioinformatics business of QIAGEN, today announced the launch of an application programming interface (API) to streamline access for customers from pharma, biotech and academia to its QIAGEN Biomedical Knowledge Base, and enable easy integration of the data into their internal systems.

The QIAGEN Biomedical Knowledge Base (QIAGEN BKB) API will allow researchers to more easily use knowledge graphs, artificial intelligence (AI) and machine learning (ML) to accelerate research into disease mechanisms and subtypes, targets and biomarkers, mechanisms of action and other areas. It will also reduce infrastructure costs for hosting and maintaining QIAGEN’s huge archive of manually curated data.

“One of the greatest challenges facing researchers today is accessing centralized, structured, normalized and high-quality data to drive data-science projects,” said Dr. Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights. “Our new API taps into the power of AI and data science by enabling easy and flexible query and export of QIAGEN BKB into data warehouses and projects. API access helps researchers push beyond the limitations of the human mind, time and purpose-built applications to enable the discovery of novel disease and drug insights.”

The QIAGEN BKB API provides direct access to the same high-quality, human-reviewed data that fuels the widely used QIAGEN Ingenuity Pathway Analysis (IPA) application, which has been used by over 40,000 scientists in pharmaceuticals, biotech and academia over the past 20 years and cited in over 57,000 scientific papers. The knowledge base structures and integrates causal biomedical relationships between genes, diseases, functions, targets, drugs, chemicals and other objects to enable the prediction and validation of novel target-disease and drug-disease relationships. The new API streamlines how data scientists can query, integrate, structure, train and interpret the data into new and existing projects.

QIAGEN BKB collects, structures and integrates information about biomedical relationships locked in thousands of publications and dozens of databases. The API will allow researchers to harness this trove more easily and quickly – and to either purchase the entire knowledge or only more targeted data, making it more attractive for smaller organizations that require smaller data volumes. Through its flexibility and granularity, the API creates new opportunities to extract profound insights to biological questions.

To learn more about QIAGEN Biomedical Knowledge Base visit

About QIAGEN Digital Insights

QIAGEN Digital Insights, the bioinformatics business of QIAGEN, is the leading provider of genomic and clinical knowledge, analysis and interpretation tools and services for scientists and clinicians. We have over 25 years of experience in the industry, 90,000 users worldwide, over 100,000 citations in scientific papers, more than 3 million profiled patient cases and over 40 billion scientific data points. Discover our portfolio of expertly curated genomic and clinical knowledge solutions as well as bioinformatics software and services for efficient data management, sharing and actionable insights. Learn more at


QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2023, QIAGEN employed more than 6,100 people in over 35 locations worldwide. Further information can be found at

Contact Global Product Management:

Venkatesh Moktali

Press Contact

Daniela Eltrop
Associate Director Public Relations
Germany: +49 2103 29 11676
Mobile: +49 152 01811676

Lisa Mannagottera
Associate Manager Public Relations
Germany: +49 2103 29 14181
Mobile: +49 152 01811381

Dr. Thomas Theuringer
Senior Director Corporate Communications & Head Of External
Germany: +49 2103 29 11826
U.S.: +1 240 686 7425
The Netherlands: +31 773 55 66 66

IR Contacts

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
Download VCARD

Alexandra Koenig
Investor Relations Coordinator
+49 2103 29 11709
Download VCARD

John Gilardi
Vice President
Head of Corporate Communications and Investor Relations
Germany +49 2103 29 11711
U.S. +1 240 686 2222
The Netherlands +31 773 55 66 66
Download VCARD

Record changed: 2024-01-20


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Qiagen (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Consultech GmbH Secure Funding with RnD Grants 650x300px

» top